{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T23:06:04Z","timestamp":1790895964708,"version":"4.1.0"},"reference-count":41,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Neurourology and Urodynamics"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>To assess the safety and efficacy of intravesical gentamicin in patients with recurrent urinary tract infections (UTI) and\/or catheter blockages.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This prospective, single\u2010center study enrolled adult patients with recurrent UTIs and\/or catheter blockages who had been prescribed intravesical gentamicin (once\u2010daily, 30\u221260\u2009mL, 0.48\u2009mg\/mL, held 60\u2009min) from June 1, 2024, to April 1, 2025. Eligible patients had received \u2265\u200914 days' intravesical gentamicin. Primary outcomes were, for patients with recurrent UTIs, subjective (patient\u2010reported) and objective (positive culture with symptoms) rates of UTI per 12\u2010month\u2010equivalent, before versus during treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Fifty\u2010five patients were prescribed intravesical gentamicin, of whom 42 were eligible. Median age was 58 years, and 26 patients (62%) were female. Thirty\u2010six patients (86%) had neurogenic bladder, and 38 (90%) had pre\u2010existing catheter use (suprapubic: 17; intermittent: 15; indwelling urethral: six). Median follow\u2010up was 6 months. Compared with pre\u2010treatment, patients experienced significantly fewer subjective (median 6.5 vs. 0;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.00001) and objective (median 5.5 vs. 0;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.00001) UTIs per 12\u2010month\u2010equivalent. Regarding secondary outcomes, for patients with recurrent UTIs, gentamicin was associated with decreased rates of UTI\u2010related emergency department presentations per 12\u2010month\u2010equivalent (median 1 vs. 0;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.005) and decreased proportion of patients with \u2265\u20091 multi\u2010drug\u2010resistant UTI (70% vs. 23%;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.00002). Median ease\u2010of\u2010use was 4\/5, and likelihood\u2010to\u2010recommend was 5\/5. Complications were reported by 11 patients (26%), all Clavien\u2212Dindo Grade I. Of patients with prior catheter blockages, 47% reported decreased catheter blockages, although duration between catheter changes was unchanged (median 28 vs. 28 days;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.53).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Intravesical gentamicin appears safe and effective prophylaxis for recurrent UTIs and\/or catheter blockages.\n                      <jats:bold>Trial Registration:<\/jats:bold>\n                      This study has been registered with the Australian New Zealand Clinical Trials Registry, submission 389972.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/nau.70239","type":"journal-article","created":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T09:25:13Z","timestamp":1773307513000},"page":"681-688","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Safety and Efficacy of Intravesical Gentamicin for Recurrent Urinary Tract Infections and\/or Catheter Blockages"],"prefix":"10.1002","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7833-2537","authenticated-orcid":false,"given":"Ned","family":"Kinnear","sequence":"first","affiliation":[{"name":"Department of Surgery, Division of Urology University of Calgary Calgary Canada"},{"name":"Alberta Bladder Centre Calgary Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lance","family":"Coleman","sequence":"additional","affiliation":[{"name":"Alberta Bladder Centre Calgary Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kara","family":"Parsons","sequence":"additional","affiliation":[{"name":"Alberta Bladder Centre Calgary Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leigh","family":"Casey","sequence":"additional","affiliation":[{"name":"Alberta Bladder Centre Calgary Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Baverstock","sequence":"additional","affiliation":[{"name":"Department of Surgery, Division of Urology University of Calgary Calgary Canada"},{"name":"Alberta Bladder Centre Calgary Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,3,12]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.sc.3101348"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(18)30279-2"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1080\/003655999750015925"},{"issue":"9","key":"e_1_2_12_5_1","first-page":"401","article-title":"Proportion of Complications in Patients Practicing Clean Intermittent Self\u2010Catheterization (CISC) vs Indwelling Catheter","volume":"56","author":"Turi M. H.","year":"2006","journal-title":"JPMA: The Journal of the Pakistan Medical Association"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.apmr.2016.12.011"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.22495"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/sc.2017.64"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000008907"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1159\/000090444"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11934-018-0834-8"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/sc.1993.42"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1177\/0954411918776691"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.25513"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.5489\/cuaj.4434"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/SPV.0000000000000810"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.70037"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.23250"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.25635"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2018.10.004"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlad040"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics11101335"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11195703"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1177\/20514158221138845"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/0090-4295(94)90249-6"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2022.01.050"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1179\/2045772312Y.0000000084"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2010.05.005"},{"key":"e_1_2_12_29_1","unstructured":"\u201cUrinary Tract Infection (Recurrent): Antimicrobial Prescribing \u201d National Institute for Health and Care Excellence (NICE) London United Kingdom 2018 https:\/\/www.nice.org.uk\/guidance\/ng112\/chapter\/recommendations."},{"key":"e_1_2_12_30_1","unstructured":"G.Bonkat J.Kranz T.Cai et al. \u201cEAU Guidelines on Urological Infections Arnhem \u201d European Association of Urology The Netherlands 2025 https:\/\/d56bochluxqnz.cloudfront.net\/documents\/full-guideline\/EAU-Guidelines-on-Urological-infections-2025.pdf."},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)34882-6"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(93)90254-M"},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.1053\/apmr.2002.26605"},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000002235"},{"key":"e_1_2_12_35_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41393-019-0251-y"},{"key":"e_1_2_12_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2005.07.018"},{"key":"e_1_2_12_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2011.03.062"},{"key":"e_1_2_12_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-0528.1960.tb07016.x"},{"key":"e_1_2_12_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)44085-7"},{"key":"e_1_2_12_40_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000011796"},{"key":"e_1_2_12_41_1","unstructured":"\u201cIntraVESical Preparations for REcurrent Urinary Tract Infection PRevention (The VESPER Study): A Multi\u2010Arm Multi\u2010Site Open Label Randomised Superiority Trial \u201d National Institute for Health and Care Research (NIHR) London United Kingdom 2024 https:\/\/fundingawards.nihr.ac.uk\/award\/NIHR158130."},{"key":"e_1_2_12_42_1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.21003"}],"container-title":["Neurourology and Urodynamics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/nau.70239","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/nau.70239","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/nau.70239","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T03:19:32Z","timestamp":1778815172000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/nau.70239"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,12]]},"references-count":41,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1002\/nau.70239"],"URL":"https:\/\/doi.org\/10.1002\/nau.70239","archive":["Portico"],"relation":{},"ISSN":["0733-2467","1520-6777"],"issn-type":[{"value":"0733-2467","type":"print"},{"value":"1520-6777","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,12]]},"assertion":[{"value":"2025-05-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}